Therapeutic area intelligence for Neurodegenerative Diseases with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Azurity Pharmaceuticals →

Assets

Edaravone →

Recent signals(1)

RegulatoryJuly 24, 2026

FDA Submission Status Update for Edaravone by Azurity Pharmaceuticals

Azurity Pharmaceuticals has submitted New Drug Application (NDA) for Edaravone under application number NDA221059.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Neurodegenerative Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.